Madrigal Pharmaceuticals Aktie
459,60
EUR
-0,70
EUR
-0,15
%
528,71
USD
+0,36
USD
+0,07
%
Madrigal Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Madrigal Pharmaceuticals Aktie Analyse
| 10.06.19 | Madrigal Pharmaceuticals Buy | B. Riley FBR | |
| 28.02.19 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 14.12.18 | Madrigal Pharmaceuticals Outperform | Wolfe Research | |
| 12.12.18 | Madrigal Pharmaceuticals Neutral | B. Riley FBR | |
| 01.06.18 | Madrigal Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 01.06.18 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 30.01.18 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 06.12.17 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
|
Werbung
|
|||
| 29.11.17 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
Werbung
Werbung